Ipsen Pharma Sas was Sutro Biopharma’s largest revenue line in fiscal 2025, bringing in $56.36M of $102.48M (55%).
| Counterparty Name | FY 2024 | FY 2025 |
|---|---|---|
| Astellas Pharma Inc. ("Astellas") | $52.87M | $45.42M |
| Ipsen Pharma Sas | $559.00K | $56.36M |
| Tasly Biopharmaceuticals Co., Ltd. ("Tasly") | $6.02M | $104.00K |
| Vaxcyte Agreement | $2.58M | $600.00K |
| Merck Sharp & Dohme Corp | $19.00K | — |
| Total | $62.04M | $102.48M |
Sutro Biopharma brought in $102.48M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Sutro Biopharma regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $62.04M. Ipsen Pharma Sas was the largest at $56.36M (55.0%), ahead of Astellas Pharma Inc. ("Astellas") at $45.42M (44.3%) and Vaxcyte Agreement at $600.00K (0.6%). The remaining revenue line, Tasly Biopharmaceuticals Co., Ltd. ("Tasly"), brought in $104.00K.
Compared with fiscal 2024, Ipsen Pharma Sas grew 9,981.8% to $56.36M, while Astellas Pharma Inc. ("Astellas") fell 14.1% to $45.42M.
Sutro Biopharma stopped reporting Merck Sharp & Dohme Corp as a separate revenue line after fiscal 2024, when it brought in $19.00K.
Sutro Biopharma (STRO) reports its revenue by counterparty name. In fiscal 2025, Ipsen Pharma Sas was its largest revenue line, bringing in $56.36M (55.0% of the total), followed by Astellas Pharma Inc. ("Astellas") at $45.42M (44.3%).
Ipsen Pharma Sas was Sutro Biopharma's largest revenue line in fiscal 2025, bringing in $56.36M, or 55.0% of the $102.48M total across its four revenue lines.
Every figure comes from Sutro Biopharma's annual financial filings, as reported. Each line keeps the name Sutro Biopharma gives it, and years follow its fiscal calendar.
Sutro Biopharma's revenue by counterparty name goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.